Peringatan Keamanan

A single case of fatal septicemia following leukopenia has been reported during clinical trials. Bone marrow depression leading to thrombocytopenia (unusual bleeding or bruising; black, tarry stools; blood in urine or stools; pinpoint red spots on skin), and leukopenia (cough or hoarseness; fever or chills; lower back or side pain; painful or difficult urination)

Strontium chloride Sr-89

DB09498

small molecule approved investigational

Deskripsi

Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer.A31264 Bone metastases is a common and severe complication presented in advanced stages of the disease. It is usually presented mainly in patients with prostatic and breast cancer, as well as in cancer of lung, bladder and thyroid. There has been some cases of apparent tumor regression which has given it a potential tumoricidal effect.A31263

Struktur Molekul 2D

Berat 159.81
Wujud liquid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Strontium chloride 89 presents a half-life of 50.5 days.[A31266]
Volume Distribusi There have been several studies regarding the pharmacokinetics of different administration routes of strontium chloride 89. The values are different but it ranges between 40-67L.[A31267, A31268]
Klirens (Clearance) Strontium chloride 89 is mainly cleared by urine on a 3:1 ratio compared with fecal excretion. The total drug clearance can be slow, giving it a long half-life.[T44]

Absorpsi

Following intravenous injection, strontium chloride 89 behaves like its calcium analog. It clears rapidly from the blood stream and selectively gets localized on the bone mineral, preferentially in zones of osteogenesis, where it can stay retained for about 14 days.FDA label

Metabolisme

Strontium can interact with components than normally bind to calcium, including hydroxyapatite (main component of mineralized bone), calcium-binding or calcium-transport proteins. It can form complexes with different inorganic anions like carbonate, citrate, phosphate, carboxylic acid or lactate.T44

Rute Eliminasi

The elimination is done mainly by urinary excretion greatly in the two first days after injection. The rest of the elimination route is found in faeces. The percentage of urinary excretion may vary depending on the presence of bone lesions.FDA label The presence of strontium chloride 89 in faeces suggests an absorption into the gastrointestinal tract either by the bile or from the plasma.T44

Interaksi Obat

0 Data
Tidak ada data.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 1379058
    Fossa SD, Paus E, Lochoff M, Backe SM, Aas M: 89Strontium in bone metastases from hormone resistant prostate cancer: palliation effect and biochemical changes. Br J Cancer. 1992 Jul;66(1):177-80.
  • PMID: 1717094
    Laing AH, Ackery DM, Bayly RJ, Buchanan RB, Lewington VJ, McEwan AJ, Macleod PM, Zivanovic MA: Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol. 1991 Sep;64(765):816-22.
  • PMID: 2477119
    Montebello JF, Hartson-Eaton M: The palliation of osseous metastasis with 32P or 89Sr compared with external beam and hemibody irradiation: a historical perspective. Cancer Invest. 1989;7(2):139-60.
  • PMID: 7684862
    Ackery D, Yardley J: Radionuclide-targeted therapy for the management of metastatic bone pain. Semin Oncol. 1993 Jun;20(3 Suppl 2):27-31.
  • PMID: 1613572
    Breen SL, Powe JE, Porter AT: Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma. J Nucl Med. 1992 Jul;33(7):1316-23.
  • PMID: 7684554
    Hansen DV, Holmes ER, Catton G, Thorne DA, Chadwick DH, Schmutz DA: Strontium-89 therapy for painful osseous metastatic prostate and breast cancer. Am Fam Physician. 1993 Jun;47(8):1795-800.
  • PMID: 1716935
    Lewington VJ, McEwan AJ, Ackery DM, Bayly RJ, Keeling DH, Macleod PM, Porter AT, Zivanovic MA: A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer. 1991;27(8):954-8.
  • PMID: 25298863
    Heianna J, Miyauchi T, Endo W, Miura N, Terui K, Kamata S, Hashimoto M: Tumor regression of multiple bone metastases from breast cancer after administration of strontium-89 chloride (Metastron). Acta Radiol Short Rep. 2014 May 10;3(4):2047981613493412. doi: 10.1177/2047981613493412. eCollection 2014 May.
Menampilkan 8 dari 13 artikel.
Textbook
  • ISBN: 978 92 4 153077 4
    Peter Watts and Paul Howe (2010). Strontium and Strontium compounds. World Health Organization.

Contoh Produk & Brand

Produk: 3 • International brands: 0
Produk
  • Metastron
    Injection, powder, lyophilized, for solution • 1 mCi/1mL • Intravenous • US • Approved
  • STRONTIUM CHLORIDE Sr-89
    Injection • 1 mCi/1mL • Intravenous • US • Generic • Approved
  • STRONTIUM CHLORIDE Sr-89
    Injection • 1 mCi/1mL • Intravenous • US • Generic • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul